BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug

Reuters03-25

BUZZ-<a href="https://laohu8.com/S/TEM">Tempus AI</a> rises after partnering with <a href="https://laohu8.com/S/DSKY">Daiichi Sankyo</a> for cancer drug

** Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket

** Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer

** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells

** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit

** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug

** Financial terms of the partnership not disclosed

** TEM shares up ~75% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622307656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622307656","market":"us","top_or_hot":-1,"title":"BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> rises after partnering with <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> for cancer drug</title></head><body><p>** Shares of genetics-testing firm Tempus AI <span>TEM.O</span> rise 2% to $49.34 premarket</p><p>** Co says it partnered with Japan's <a href=\"https://laohu8.com/S/DSKYF\">Daiichi Sankyo</a> to use AI to speedily develop a drug for cancer</p><p>** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells</p><p>** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit </p><p>** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug </p><p>** Financial terms of the partnership not disclosed </p><p>** TEM shares up ~75% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> rises after partnering with <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> for cancer drug</title></head><body><p>** Shares of genetics-testing firm Tempus AI <span>TEM.O</span> rise 2% to $49.34 premarket</p><p>** Co says it partnered with Japan's <a href=\"https://laohu8.com/S/DSKYF\">Daiichi Sankyo</a> to use AI to speedily develop a drug for cancer</p><p>** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells</p><p>** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit </p><p>** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug </p><p>** Financial terms of the partnership not disclosed </p><p>** TEM shares up ~75% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D15T:1","article_id":"2622307656","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622307656","pubTimestamp":1774442934,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug** Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket** Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit ** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug ** Financial terms of the partnership not disclosed ** TEM shares up ~75% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEMT":"2倍做多TEM ETF-Tradr","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4613":"AI应用软件","BK4611":"AI医疗","BK4121":"生命科学工具和服务","TEM":"Tempus AI"},"translate_title":"BUZZ-Tempus AI与第一三共合作开发癌症药物后崛起","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEMT":0.6,"TEM":1.96},"content_text":"BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug** Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket** Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit ** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug ** Financial terms of the partnership not disclosed ** TEM shares up ~75% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622307656","isCrawlerRequest":true}